•
NB
NBTX
Nanobiotix S.A. American Depositary Shares
polygon--
Price Chart
Market Cap
970.66M
Volume
5.74K
52W High
$30.35
52W Low
$2.95
Open
$21.05
Prev Close
$20.06
Day Range
21.02 - 21.41
About Nanobiotix S.A. American Depositary Shares
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
Latest News
Nanobiotechnology Market to Hit USD 420.2 Billion by 2034, Fueled by 2025 Traffic Growth and Strategic Material & Product Innovations
GlobeNewswire Inc.•Dec 17
NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
GlobeNewswire Inc.•Dec 15
NANOBIOTIX va intégrer les indices CAC Mid 60 et SBF 120 d’Euronext Paris
GlobeNewswire Inc.•Dec 15
Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue
The Motley Fool•Nov 24
NANOBIOTIX annonce de nouveaux résultats de Phase 1 qui continuent de confirmer le potentiel de JNJ-1900 (NBTXR3), avec un anti-PD-1, en tant que potentielle nouvelle option thérapeutique de première ou deuxième ligne ou plus dans le CETEC R/M naïf ou résistant aux anti-PD-1
GlobeNewswire Inc.•Sep 29
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
GlobeNewswire Inc.•Sep 29
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
GlobeNewswire Inc.•Apr 30
Nanobiotix présente les résultats complets de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) dans le cancer du pancréas et organise une conférence téléphonique et webcast
GlobeNewswire Inc.•Apr 30